found to be secondary to a congenital hypercoagulable state (hyperhomocysteinemia with MTHFR mutation). DSRS was performed electively 5 months later for recurrent nonmassive hemorrhage. The patient developed worsening ascites and a CT performed 8 days postoperatively suggested DSRS thrombosis, which led to referral. Via a right femoral vein approach, the expected location of the shunt at the left adrenal vein was probed with a 2.8F microcatheter and microwire via a 5F catheter. The shunt anastomosis was crossed with a venogram revealing a severe anastomotic stenosis in the splenic vein (Fig, A) . The system was exchanged for a 5F sheath, and via the sheath, a 5-mm Â 18-mm stent was deployed across the anastomotic stenosis. Poststent images demonstrated an improved caliber and flow but a small amount of nonocclusive residual thrombus within the shunt. Suction thrombectomy was performed via the guiding sheath. Post-treatment images demonstrated restored patency with resolution of thrombus and draining of the splenic vein into the left renal vein (Fig, B) .
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Persistent Symptoms After Endovenous Thermal Ablation: Proximal Venous Outflow Obstruction in Superficial Venous Disease
Sneha Subramaniam, Chien Yi M. Png, Jacob Lurie, Sida Chen, Ageliki Vouyouka, Peter Faries, Michael Marin, Windsor Ting. Icahn School of Medicine at Mount Sinai, New York, NY Objectives: Symptomatic relief after endovenous thermal ablation (EVTA) is incomplete in some patients after the ablative procedure despite closure of the insufficient saphenous vein and associated varicosities. In past patients who had undergone vein stents for chronic proximal venous outflow obstruction (PVOO), we have observed some patients had a history of varicose veins and prior EVTA. This study was undertaken to establish a better understanding of patients with chronic PVOO and superficial venous disease.
Methods: .Medical records of 484 patients who underwent vein stent placement for chronic PVOO from 2013 to 2016 were retrospectively reviewed; of these, 78 patients had EVTA prior to vein stenting and met inclusion criteria: persistent venous disease symptoms, of which edema was the primary symptom, prior EVTA of the saphenous vein, a venous duplex scan that confirmed the closure of superficial veins from prior EVTA, and PVOO in the iliac vein as suggested by a computed tomography or magnetic resonance venogram. Vein stent outcome was determined by patient report and clinical assessment. Wilcoxon-Mann-Whitney tests were performed for categoric variables. Additionally, Kruskal-Wallis tests were run for ordinal variables, as well as logistic regressions for outcomes at 30 days, 90 days, 6 months, and 1 year postoperation.
Results: Of 78 patients (48 females [61.5%]), average age was 59.7 years, and median follow-up time was 352 days. There was no significant difference in outcome between CEAP classes or in the number of stents placed based on Kruskal-Wallis. The Table reports the outcome after vein stents at 30 days, 90 days, 6 months, and 1 year. Thirty-eight (48.7%) reported major improvement at 30 days, 39 (50%) reported major improvement, and 14 (18%) felt complete relief by 90 days. WilcoxonMann-Whitney tests were significant for major improvement among patients with prestent edema after EVTA at 30 (P ¼ .022) and 90 days (P ¼ .026). Ordered logistic regressions also found that the presence of edema could predict increased improvement at 30 (95% confidence interval, 0.57-7.22; P ¼ .022) and 90 days (95% confidence interval, 0.03-6.18; P ¼ .048).While 45.5% felt major improvement and 22.3% felt complete relief at 6 months, and 47.9% felt major improvement and 22.3% felt normal at 1 year, these values were not statistically significant.
Conclusions: Superficial venous disease and PVOO may coexist, and both may contribute to venous symptoms. Persistent symptoms after EVTA suggest possible presence of concurrent PVOO, and evaluation should be considered. If diagnosis is confirmed, venous stenting in persistently symptomatic patients after EVTA appears to be a safe and potential way to effectively further improve symptoms in early postoperative period.
Author Disclosures: S. Chen: Nothing to disclose; P. Faries: Nothing to disclose; J. Lurie: Nothing to disclose; M. Marin: Nothing to disclose; C. M. Png: Nothing to disclose; S. Subramaniam: Nothing to disclose; W. Ting: Janssen Pharmaceuticals: consulting fees (eg, advisory boards), speaker's bureau; A. Vouyouka: Nothing to disclose. Objectives: Radiofrequency ablation (RFA) has become the primary modality of treating perforator vein insufficiency and is being increasingly used in venous ulcer healing. Previous studies have shown a closure rate of 60% to 80% in incompetent perforator veins (IPVs) with RFA. The purpose of the study was to determine utility of a redo RFA for symptomatic recanalized perforators and predict factors associated with recanalization.
IP261.
Success Rate and Predictive Factors for Redo Radiofrequency Ablation of Perforator Veins
Methods: A retrospective analysis of 642 procedures in 256 patients with venous insufficiency due to IPVs treated with RFA from 2009 to 2015 was conducted. A redo ablation was done in 52 IPVs (28 patients), including 13 women, with mean (standard deviation) age of 65 6 15 years. The patients had presenting symptoms of CEAP: 0, C 1 ; 0, C 2 ; 5, C 3 ; 13, C 4a ; 9, C 4b ; 0, C 5 ; and 25, C 6 . The 52 IPVs were distributed in the calf (40) and 
